about
Biomarkers of Parkinson's disease: present and futureEmerging preclinical pharmacological targets for Parkinson's diseaseFocus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimer's and Parkinson's DiseaseExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesThe Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-AnalysisTranscriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease.Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosisAlpha-synuclein and tau: teammates in neurodegeneration?Chronic traumatic encephalopathy and other neurodegenerative proteinopathiesPredicting parkinsonism: new opportunities from Gaucher disease.CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluidHippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility studyCerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directionsUnbiased approaches to biomarker discovery in neurodegenerative diseasesAlpha-synuclein levels in blood plasma decline with healthy aging.Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases.Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysisCSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson DiseaseMolecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's DiseasesParkinson's disease biomarkers: resources for discovery and validation.Exosomes, an Unmasked Culprit in Neurodegenerative Diseases.Clinical biospecimens: reference materials, certified for nominal properties?Recent developments in biomarkers in Parkinson diseaseTargeting leucine-rich repeat kinase 2 in Parkinson's disease.Biomarker time out.Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.Oxidized DJ-1 as a possible biomarker of Parkinson's diseaseAdvances in non-dopaminergic treatments for Parkinson's diseaseCerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Psychiatric disturbances regulate the innate immune system in CSF of conscious mice.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.How many biomarkers to discriminate neurodegenerative dementia?The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.
P2860
Q24170134-155A6519-14C5-496D-BFE3-E1544E1ABAB7Q26764724-150B9AD5-C748-407D-B4C7-0B1330EE2133Q26767264-455204B0-E424-4409-BFD2-F0D8541AAD9BQ26770708-EEBD8158-0907-4126-BD33-5BBBB64E80D6Q26785974-529C6D98-CCF5-424F-BCEA-80FC3A5FC7B6Q27333599-6158662B-8C9A-43F6-BF3F-6E27B31069BEQ28082380-1D2E2081-9FD2-4FEE-82ED-7BD9D08B92A5Q28250508-B1B9DC1A-026B-47D8-80C0-92F12CDBADB0Q28395193-590809CC-7D6E-4934-86DB-9E41B0100767Q30432618-455C2AD9-E93F-4C8D-AD5E-A1B916F4EBA0Q31144959-C945DFD7-BD91-493C-BD3F-1A38268EB6FDQ33771776-38E183EF-D020-46FC-88D1-FDA6650F793EQ33831118-E5B22F06-00CE-4CF9-860D-7CBD15AD9383Q33917300-6CB7C3F4-0215-4975-BC69-F4FC69C82A6BQ34118169-739BD991-464C-4C0D-92EF-62F3E76989DAQ34237637-34738785-CC27-47C1-8646-C6F9D1DA9310Q34625918-53B5A1C2-6070-41A8-BD36-C1EA16169955Q35284843-465D8003-5DDB-4A0B-8FFE-FA6AF6A559E1Q35357984-3E5E0AEE-BBA6-4875-AEA5-62F2E0BFC412Q35772659-AD62C988-2A5A-42E7-BE0D-CFD6F8A2937BQ35857978-5D315BCF-E288-4FEC-9B56-982428903846Q35969183-879AF613-0E6D-402B-800D-2782EDF35CD1Q36051094-6F5411DE-DC54-4648-84B5-34F9CC6321A9Q36535217-E5D8808E-6F2A-45E4-AECB-C8257659BB37Q36724965-97549825-BA68-4A97-91D5-002B5227D361Q37053721-07E38906-F2C6-4403-8BA0-A3DDF48AF4B2Q37379512-205BAA68-21E2-45CC-8668-10A9885AAE58Q37614565-2F6CCF9C-1166-4D2E-BB73-14E185A44049Q37716309-F8D93DF2-C072-4309-A441-B103DFAC1C81Q38119095-3469D66A-F4A2-4CAD-BDA5-E69A6A8A154CQ38160939-DE6DD117-440F-4944-9638-12FB75FC26CAQ38190038-AF588A52-10D7-462B-8327-D7E0A39CAAB1Q38207538-8B8B9E15-6AA6-4A13-A57C-64706FD41E14Q38217361-0B373C75-2376-446C-978F-B441FFB8A6EFQ38218083-1316C840-F62A-402F-856D-9301AC6B2259Q38289739-9CB2DAFE-C78C-44D0-A59B-68476E3C707DQ38517137-4CC3770F-5BB5-43B7-911D-F7AD6F674E3DQ38541943-7ADBC823-7C4B-41FC-BE6A-47BE94889010Q38570242-498736BC-8BF1-4B48-90E7-85CA5632E347Q38575114-0D13F8EB-0FA3-464B-8CB9-05827A3B963E
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cerebrospinal fluid biomarkers in Parkinson disease.
@en
type
label
Cerebrospinal fluid biomarkers in Parkinson disease.
@en
prefLabel
Cerebrospinal fluid biomarkers in Parkinson disease.
@en
P2093
P2860
P921
P356
P1476
Cerebrospinal fluid biomarkers in Parkinson disease.
@en
P2093
Anna Castrioto
Davide Chiasserini
Emanuele Persichetti
Lucilla Parnetti
Nicola Tambasco
Omar El-Agnaf
Paolo Calabresi
P2860
P2888
P304
P356
10.1038/NRNEUROL.2013.10
P407
P577
2013-02-19T00:00:00Z
P5875
P6179
1018323087